WARREN, N.J., Oct. 1, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of pediatric and adult patients living with phenylketonuria (PKU). A Prescription Drug User Fee Act (PDUFA) target action date is expected to be provided in the Day 74 Letter. "The FDA filing acceptance for sepiapterin is a critical milestone toward bringing this potential important therapy to children and adults livi ...

Collaboration to Drive PTC's Onshape Initiatives Including Discovery Program, Onshape AI Advisor, and CAD and PDM Conversion Tools BOSTON, Sept. 25, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced entry into a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to accelerate the growth of its Onshape® cloud-native computer-aided design (CAD) and product data management (PDM) solution. This collaboration will focus on advancing Onshape product enhancements, customer adoption program ...

Looking for explosive stocks? These companies have what it takes to crush the market. The S&P 500 index has soared to new highs in 2024 and is currently up roughly 18% across the year's trading. Several megacap companies, including Nvidia and Meta Platforms, have posted incredible gains across the stretch and helped power big gains for the benchmark index. However, it would be a mistake for investors to overlook promising companies that have underperformed the benchmark index. With that in mind, read on to ...

SolStock PTC Therapeutics, Inc. (NASDAQ:PTCT) continues to make significant progress in its pipeline. This is especially true when you consider that it has already been able to report positive interim results from its phase 2 PIVOT-HD study, which used PTC518 for the treatment of patients with Huntington's Disease [HD]. The last time I wrote about this article in a Seeking Alpha article entitled "PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts," data for PTC518 was not released. Not o ...

BOSTON, Sept. 3, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Rob Bernshteyn to its Board of Directors, effective September 9, 2024. Bernshteyn has held leadership and executive roles in the enterprise software space for over 30 years, including 14 years as CEO and Chairman of Coupa Software, a provider of business spend management solutions. During his tenure at Coupa, Bernshteyn transformed the company into a high-growth industry leader and led a successful IPO in 2016. He ...

It has been about a month since the last earnings report for PTC Inc. (PTC) . Shares have added about 0.7% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is PTC Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. PTC's Q3 Earnings Meet Estimates PTC reported third ...

WARREN, N.J., Aug. 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Thursday, Sept. 5 at 9:15 am ET 2024 Wells Fargo Healthcare Conference Friday, Sept. 6 at 12:00 pm ET Cantor 2024 Global Healthcare Conference Tuesday, Sept. 17 at 2:30 pm ET The presentations will be webcast live on the Events and Presentations page under the Investor section o ...

BOSTON, Aug. 27, 2024 /PRNewswire/ -- PTC (Nasdaq: PTC) today announced that it will participate in the following conferences. What: Citi's 2024 Global TMT Conference When: Wednesday, September 4th, 2024 at 8:20am ET What: 2024 RBCCM Global TIMT Conference When: Tuesday, November 19th, 2024 What: Barclays 22nd Annual Global Technology Conference When: Wednesday, December 11th, 2024 What: Nasdaq 51st Investor Conference When: Wednesday, December 11th, 2024 To view the webcast and replay for conferences pleas ...

This industrial software company continues to grow its key metric and cash flow. Industrial software stock PTC (PTC 1.60%) is the sort of company investors should consider buying into on a dip. The company's recent third-quarter results, for the period ended June 30, and commentary on its fiscal 2025 were impressive in the current environment, and this company's long-term growth is only starting. Here's why PTC is a great stock for long-term holders. Attractive end markets PTC's software solutions help cust ...

– Continued strong revenue performance – – NDAs for sepiapterin and Translarna™ submitted to FDA – – Positive interim data readout from PTC518 PIVOT-HD study – – On track to achieve remaining 2024 clinical and regulatory milestones – WARREN, N.J., Aug. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2024. "I am proud of our team's continued outstanding execution as we have accomplished all our obje ...